Alzheimer’s disease has long exasperated researchers and patients alike for its seeming impossibility to be treated, let alone cured. The pile of investigational therapies that once showed theoretical promise, but failed to translate this into clinical success, is ever-growing.
This could soon change. Lecanemab, an investigational drug candidate jointly developed by Biogen and Eisai, made international headlines last September...